UCB SA (OTCMKTS:UCBJY) Sees Large Increase in Short Interest

UCB SA (OTCMKTS:UCBJY) was the recipient of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 2,600 shares, a growth of 1,200.0% from the March 31st total of 200 shares. Based on an average daily trading volume, of 24,200 shares, the days-to-cover ratio is presently 0.1 days.

UCB Trading Up 3.9 %

UCBJY stock opened at $67.30 on Friday. UCB has a 12-month low of $34.85 and a 12-month high of $67.30. The business’s fifty day moving average price is $59.36 and its 200 day moving average price is $47.89.

UCB Cuts Dividend

The company also recently disclosed a dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 29th will be issued a $0.4574 dividend. The ex-dividend date is Friday, April 26th. This represents a dividend yield of 0.71%. UCB’s dividend payout ratio is presently 46.55%.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.